Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Proteus Syndrome 1

Interventions

pembrolizumab 522 Specimen Handling 383 Carboplatin 375 Magnetic Resonance Spectroscopy 338 Cisplatin 331 Nivolumab 308 Cyclophosphamide 299 Radiotherapy 256 Paclitaxel 256 Gemcitabine 236 Biopsy 235 Bevacizumab 215 Dexamethasone 170 durvalumab 167 Oxaliplatin 163 Capecitabine 159 Rituximab 156 Fluorouracil 149 venetoclax 147 Docetaxel 147 Etoposide 142 Drug Therapy 141 atezolizumab 140 Doxorubicin 134 Ipilimumab 130 Prednisone 120 Radiosurgery 119 Lenalidomide 119 Leucovorin 113 fludarabine 110

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Miransertib × 1 year × Clear all

NCT04316546 2026-06-03

MK-7075 (Miransertib) in Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting

Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡